Literature DB >> 32509766

Hemodynamic Changes Associated with Mydriatic Eye Drop Administration in Anesthetized Pediatric Patients.

Vittoria Arslan-Carlon1, Maria C Walline2, Kenneth Seier3, Kay See Tan3, David H Abramson4.   

Abstract

BACKGROUND: Dilating eye drops are routinely used in pediatric retinoblastoma patients during anesthetized ophthalmologic exams. Information on the systemic effects of ocular mydriatics, especially in anesthetized pediatric patients, is limited.
OBJECTIVE: The primary aim of this study was to analyze hemodynamic changes during mydriatic eye drop administration in anesthetized pediatric patients.
METHODS: A retrospective chart review was performed for pediatric retinoblastoma patients who underwent MRI with anesthesia. Baseline blood pressure (BP) and heart rate (HR) were charted for each patient at induction. HR and mean arterial pressure (MAP) measurements were recorded at 5, 10, 15, 30, and 45 min after eye drop administration. Secondarily, we included data from 15 patients who received dilating eye drops while under sevoflurane general anesthetic. All patients were dilated with phenylephrine 2.5 or 10% (depending on age) and tropicamide 1%.
RESULTS: The final analysis included 176 anesthesia encounters. The results demonstrate no statistically significant deviation of more than 20% from baseline for either HR or MAP. Additionally, we did not detect any difference between patients who were anesthetized with propofol versus sevoflurane.
CONCLUSIONS: We did not observe significant hemodynamic instability with administration of dilating eye drops during propofol anesthesia.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Mydriatics; Pediatric anesthesia; Phenylephrine; Retinoblastoma; Tropicamide

Year:  2019        PMID: 32509766      PMCID: PMC7250338          DOI: 10.1159/000500593

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  8 in total

1.  Mydriatic and cardiovascular effects of phenylephrine 2.5% versus phenylephrine 10%, both associated with tropicamide 1%.

Authors:  Mario M S Motta; Jacqueline Coblentz; Bruno F Fernandes; Miguel N Burnier
Journal:  Ophthalmic Res       Date:  2009-05-27       Impact factor: 2.892

2.  The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants.

Authors:  O Elibol; T Alçelik; N Yüksel; Y Caglar
Journal:  Acta Ophthalmol Scand       Date:  1997-04

Review 3.  Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis.

Authors:  Bethany Stavert; Myra B McGuinness; C Alex Harper; Robyn H Guymer; Robert P Finger
Journal:  JAMA Ophthalmol       Date:  2015-06       Impact factor: 7.389

4.  Phenylephrine eye drops in pediatric patients undergoing ophthalmic surgery: incidence, presentation, and management of complications during general anesthesia.

Authors:  Fabio Sbaraglia; Nadia Mores; Rossella Garra; Giuseppe Giuratrabocchetta; Domenico Lepore; Fernando Molle; Gustavo Savino; Marco Piastra; Silvia Pulitano'; Maria Sammartino
Journal:  Paediatr Anaesth       Date:  2013-12-19       Impact factor: 2.556

5.  Systemic absorption and cardiovascular effects of phenylephrine eyedrops.

Authors:  V Kumar; R D Schoenwald; D S Chien; A J Packer; W W Choi
Journal:  Am J Ophthalmol       Date:  1985-02-15       Impact factor: 5.258

6.  Lack of side effects from topically administered 10% phenylephrine eyedrops. A controlled study.

Authors:  M M Brown; G C Brown; G L Spaeth
Journal:  Arch Ophthalmol       Date:  1980-03

Review 7.  Systemic side effects of eye drops: a pharmacokinetic perspective.

Authors:  Andre Farkouh; Peter Frigo; Martin Czejka
Journal:  Clin Ophthalmol       Date:  2016-12-07

8.  A Single Drop in the Eye - Effects on the Whole Body?

Authors:  Anu Vaajanen; Heikki Vapaatalo
Journal:  Open Ophthalmol J       Date:  2017-10-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.